20.01.2021 Merck KGaA  DE0006599905

DGAP-Adhoc: Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial ([email protected] Lung 037)


 

DGAP-Ad-hoc: Merck KGaA / Key word(s): Study/Study results
Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial ([email protected] Lung 037)

20-Jan-2021 / 13:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Merck KGaA (the "Company") is investigating a bifunctional immunotherapy, bintrafusp alfa (anti-PD-L1/TGF-beta trap), as a potential therapy for difficult to treat cancers.

While reviewing the totality of data from the ongoing clinical trial [email protected] Lung 037 in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) that have high expression of PD-L1 (the "Clinical Trial"), the Independent Data Monitoring Committee recommended on January 19, 2021 to discontinue the Clinical Trial. Based on this recommendation, the Company has made the decision to discontinue the Clinical Trial, as the
study is unlikely to meet the primary efficacy endpoint. The recommendation by the Independent Data Monitoring Committee and the Company's decision is related only to this Clinical Trial.

Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world.

An investor and analyst call with the Company's management is scheduled for 2:00 pm (CET).



Andreas Cezanne - Head of Corporate Media Relations
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151-14542702

20-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Phone: +49 (0)6151 72 - 6328
E-mail: [email protected]
Internet: https://www.merckgroup.com/de
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX
EQS News ID: 1161977

 
End of Announcement DGAP News Service

1161977  20-Jan-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1161977&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 15.024,00 15.327,00 14.836,00 16.152,00 17.534,00 19.687,00 0,00
EBITDA1,2 4.415,00 4.282,00 3.528,00 4.066,00 4.923,00 5.946,00 0,00
EBITDA-Marge3 29,39 27,94 23,78 25,17 28,08 30,20 0,00
EBIT1,4 2.481,00 2.525,00 1.727,00 2.120,00 2.985,00 4.179,00 0,00
EBIT-Marge5 16,51 16,47 11,64 13,13 17,02 21,23 0,00
Jahresüberschuss1 1.633,00 2.610,00 3.396,00 1.324,00 1.994,00 3.065,00 0,00
Netto-Marge6 10,87 17,03 22,89 8,20 11,37 15,57 0,00
Cashflow1,7 2.518,00 2.696,00 2.219,00 2.856,00 3.477,00 4.616,00 0,00
Ergebnis je Aktie8 3,75 5,99 7,76 3,04 4,57 7,03 8,85
Dividende8 1,20 1,25 1,25 1,30 1,40 1,85 2,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Merck
WKN Kurs in € Einschätzung Börsenwert in Mio. €
659990 177,350 Kaufen 77.107,86
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
18,47 25,57 0,72 39,59
KBV KCV KUV EV/EBITDA
3,65 16,70 3,92 15,04
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
2,00 2,15 1,13 28.04.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.05.2023 04.08.2022 10.11.2022 02.03.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,67% 2,11% -21,87% -16,97%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Merck KGaA  ISIN: DE0006599905 können Sie bei EQS abrufen


Gesundheit , 659990 , MRK , XETR:MRK